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Patients with peritoneal carcinomatosis (PC) from colorectal origin may undergo
cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
as a curative approach. One major prognostic factor that affects survival is
completeness of cytoreduction. Molecular Fluorescence Guided Surgery (MFGS) is a
novel intraoperative imaging technique that may improve tumor identification in the
future, potentially preventing over- and under-treatment in these patients. This
narrative review outlines a chronological overview of MFGS development in patients
with PC of colorectal origin.
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1 | INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers
worldwide, with an incidence of 40 patients per 100 000 population
and a mortality rate of 15 per 100 000 persons.1,2 Of these patients,
8-25% develop peritoneal carcinomatosis (PC).3–6 Over the past
decades, the treatment of PC of colorectal origin has evolved
considerably, from palliative care toward a more successful treatment
approach with curative intent.7,8 In particular, the introduction of
cytoreductive surgery (CRS) combined with hyperthermic intraperito-
neal chemotherapy (HIPEC) has contributed significantly to this
change.9,10 After surgical cytoreduction of all macroscopic tumor
tissue, the abdominal cavity is perfused with heated chemotherapy in
order to eliminate remaining microscopic disease. Up to date, only one
randomized clinical trial has been performed studying patients with PC
of colorectal origin. A median overall survival of 22 months was seen
for patients after undergoing CRS in combination with HIPEC,
compared to 13 months for patients receiving only systemic
chemotherapy with or without palliative surgery.11,12 The authors
report a 5-years survival of 43% for patients in whom all macroscopic
tumor was removed, compared to 0% for patients in whom residual
lesions of more than 2.5 mm were left behind.11 These findings
emphasize the importance of patient selection and a macroscopically
complete cytoreduction, mainly because incomplete cytoreduction
followed by HIPEC does not contribute to a prolonged survival, but
potentially does introduce a high risk of postoperative complications,
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an extensive rehabilitation period and subsequently decreased quality
of life.12–15
Although the technical quality of the complete CRS/HIPEC
procedure has improved, still up to 88% of the patients undergoing
CRS and HIPEC for PC of CRC develop recurrent disease within
2 years.16 Currently, many imaging modalities are available for
preoperative staging, such as ultrasonography, computed tomography
(CT), magnetic resonance imaging (MRI), or positron emission tomogra-
phy (PET) scans. Unfortunately, all of these imaging modalities are
insufficient for the preoperative assessment of tumor load, or
determination of a preoperative Peritoneal Cancer Index (PCI), the
most important staging system in PC. CT, MRI, and fluorodeoxyglucose
(FDG-) PET scans have a poor sensitivity and specificity to estimate PCI
by detection of individual tumor deposits, due to the limited spatial
resolution.17 For example, the detection of individual peritoneal
deposits using a CT-scan varies from 9.1 to 24.3% for tumor sizes
<1 cm, to up to 59.3-66.7% for tumor size of over 5 cm.18 These results
are in accordancewith other previous studies.19–21Current hybrid PET/
CT scanners have a limited spatial resolution of 5-8mm,22 whereasMRI
seems to be more promising in detecting peritoneal lesions.23
For intraoperative differentiation between benign and malignant
lesions, surgeons currently depend on visual and tactile inspection only.
Unfortunately, the human eye and palpation are not competent enough
to detect molecular changes in intra-abdominal lesions that have the
same color and physical properties, or to distinguish tumor lesions from
benign scar tissue originating from previous surgery. Today, to the best
of our knowledge, no intraoperative imagingmodalities provided by the
more classical modalities like PET, are available to assist in the real-time
identification of peritoneal cancer deposits, loco-regional metastases,
and tumor-positive resection margins.
Considering the high tumor recurrence rates after the CRS and
HIPEC procedure, there is a clear need for an imagingmodality that can
aid the oncological surgeon in the differentiation between tumor and
benign tissue intraoperatively. In recent years, optical molecular
imaging using tumor-targeted fluorescence tracers has emerged as a
promising imaging technique for real-time guidance in oncological
surgery.24–26 This technique can be applied intraoperatively to serve as
a “red-flag” imaging technique to assist in optimal tumor identification.
Improved detection of tumor tissue could not only help attain a more
complete cytoreduction, but might also facilitate tailored surgery,
avoiding unnecessary resections of benign lesions and organs.
This narrative review explains the principles of intraoperative
optical molecular imaging and provides a chronological overview of the
development of Molecular Fluorescence Guided Surgery (MFGS) in
patients with PC of colorectal origin.
2 | PRINCIPLES OF INTRAOPERATIVE
OPTICAL MOLECULAR IMAGING
In colorectal surgery, as in surgical oncology in general, radical surgery
and tumor-free resection margins are essential for optimizing patient
prognosis. Optical molecular imaging using fluorescence imaging
agents can provide real-time intraoperative feedback with high
resolution, that is in concordance with the natural surgical field of
view of a surgeon and based on the molecular characteristics of the
tissue (Figure 1). The technique makes use of non-ionizing imaging
agents and can be implemented relatively easily in the current surgical
workflow.
Over the past decades, there has been an increased interest in the
clinical application of optical molecular imaging using fluorescence
imaging agents. Fluorescence occurswhen a photon or fluorescent dye
absorbs light at a certain wavelength, subsequently triggering the
release of a photon with a longer wavelength.27 The quality of
fluorescence imaging is influenced by different factors such as changes
in photon directions (ie, scattering) and absorption of photons by the
tissue. Multiple tissue components play an important role in
fluorophore absorption, with the most relevant being hemoglobin,
water, and lipids. As the scattering and absorption properties of tissue
are lower in light with longer wavelengths, the near-infrared (NIR) light
spectrum (700-900 nm) is considered the optimal clinical diagnostic
window for fluorescence imaging.28 These characteristics result in
deeper penetration depths of up to one to three centimeters that can
be obtained in the NIR light spectrum, leading to higher signal-to-
background (SBR) ratios compared to the visible light spectrum (ie, red-
green-blue white-light, 380-700 nm).29,30
NIR fluorescence light is invisible to the human eye and therefore
special imaging devices are required to visualize fluorescence during
surgery. In general, these camera systems are equipped with two
different light sources: a white-light source and a NIR fluorescence
light source. Due to the use of a dichroic mirror and specific filters
installed in the camera system itself, the visible light derived from the
tissue can be separated from NIR fluorescence light, which enables
simultaneous imaging of both visible and NIR fluorescence light. Next
to that, an overlay of fluorescence signals can be projected on the
“normal” white-light images by use of computer software.27 In the
operating theatre, all three images can be displayed on monitors at the
same time, providing real-time imaging related to the natural surgical
field of view (Figure 2). Currently, there are several different
intraoperative NIR fluorescence imaging devices available for research
and clinical use.31–38
Fluorescence signals in tissue arise by either an endogenous tissue
component (ie, autofluorescence), or an intravenously administered
exogenous optical contrast agent. At present, various types of optical
contrast agents are available enabling intraoperative imaging, which
can roughly be divided into non-targeted and targeted imaging agents.
The effect of non-targeted imaging agents is mainly based on
vascularization and perfusion (ie, also the so-called Enhanced
Permeability and Retention (EPR) effect), whereas targeted imaging
agents specifically bind to a receptor or protein that is present in a
tumor cell. Due to genetic alterations that occur in cancer
development, various receptors and proteins become upregulated,
which can potentially be used as targets for imaging purposes.39
Prior to developing such targeted imaging agents, it is essential to
identify which genes or proteins become upregulated for each
specific tumor type.40,41
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3 | UPREGULATED GENES AND PROTEINS
RELATED TO CRC
The potential application of targeted imaging agents for intraoperative
tumor visualization is dependent on the expression levels of
biomarkers. A biomarker is a specific component present on or
secreted by the tumor cell itself.
Most colorectal cancers are thought to develop via the “adenoma-
to-carcinoma sequence,” arising from normal cells through the
stepwise asset of different genetic alterations.42,43 In these expressed
FIGURE 1 Concept of molecular fluorescence guided surgery (MFGS). Prior to surgery a fluorescent target tracer is injected intravenously
(A). During the operation the surgeon will receive real-time feedback by a molecular fluorescence camera in the detection tumor tissue (B).
Unpublished figure from previously published study Harlaar et al107
FIGURE 2 Intraoperative imaging with white-light, NIR fluorescence and the overlay of both. Intraoperative imaging of a patient with PC
of colorectal origin following intravenous administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW targeting VEGF-A. A white-
light image (A), NIR fluorescence image (B), and overlay of both (C) clearly show fluorescent signals at the location of a clinically suspect
peritoneal lesion. Back-table imaging directly after surgery of a different peritoneal lesion of the same patient is depicted (D-F). Both
peritoneal lesions proved to be tumor metastasis upon final histopathology. Unpublished figures from previously published study Harlaar
et al.107
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genes different functional categories can be identified: genes related
to proliferation and metabolic rates, to cell adhesion and communica-
tion, to transcription and mitosis regulation, or to apoptosis.44,45
Knowing which biomarkers are encoded by which genes is important
when searching for which target to develop a fluorescence imaging
agent for.
Cardoso et al44 presented a list of 128 different genes that were
found to be upregulated in CRC compared to normal colorectal tissue.
Since protein expression is not always synchronously upregulated, not
all of these genes result in overexpression of the related proteins or
receptors. Previously, an extensive literature search has been
performed on this specific list of genes, in order to identify which
genes gave an upregulation of the related proteins or receptors as
confirmed by immunohistochemical analysis. 46 As a result, 29 targets
were identified, that could be used for imaging purposes during CRC
surgery.
4 | TARGET SELECTION CRITERIA (TASC)
To select the most optimal target for imaging purposes from this large
set of upregulated biomarkers, the TArget Selection Criteria (TASC)
scoring system was developed.46 The aim of the TASC was to improve
the selection of suitable biomarkers for tumor-targeted imaging of all
types of cancer. Seven of the most relevant target characteristics were
identified based on literature, that each could be scored with 0-6
points. The following characteristics were identified by which a
biomarker is validated: i) extracellular biomarker localization—either on
the cell membrane or in close proximity of the tumor cell; ii) expression
pattern; iii) tumor-to-healthy tissue ratio (T/N); iv) percentage of
positive tumors; v) reported successful use of the biomarker in in vivo
imaging studies; vi) enzymatic activity; and vii) internalization.46 Based
on extensive testing of the TASC on a variety of biomarkers, cut-off
values were determined for target selection. A total score of 18 or
more indicates that a biomarker can be considered a potential
candidate for tumor-targeted imaging.
Asmentionedbefore,29 targetswere identified thatmaybeusedas
potential targets for intraoperative imaging of CRC.46 Using the TASC-
scoring system, six biomarkers were considered the most promising:
EpithelialCellAdhesionMolecule (EpCAM),CXCChemokineReceptor4
(CXCR4), Mucin 1 (Muc1), Matrix MetalloProteinases (MMPs), Epider-
mal Growth Factor Receptor (EGFR), and Carcino-Embryonic Antigen
(CEA). Although the Vascular Endothelial Growth Factor-A (VEGF-A)
scored a total of 17 points, it was still considered a suitable potential
target aswell, given the extensive experience therealready is inVEGF-A
targeted imaging. For the clinical translation of these seven suitable
biomarkers, specific fluorescence imaging agents need to be available to
facilitate MFGS of CRC and PC of colorectal origin.
5 | FLUORESCENCE IMAGING AGENTS
As stated before, fluorescence imaging agents or probes that can be
used for MFGS can roughly be divided into two categories:
non-targeted fluorescent probes and targeted fluorescent probes.
The main difference between these two categories is based on their
mechanism of action (MOA).
5.1 | Non-targeted fluorescent probes
Non-targeted fluorescent probes accumulate “passively” in solid
tumors due to physiological properties such as increased
angiogenesis, pressure differences, and high metabolic activity
(Figure 3A). It is commonly known that the majority of solid
tumor cells stimulate angiogenesis and therefore are highly
vascularized. This feature combined with the lack of efficient
lymphatic drainage results in more accumulation in tumor tissue
compared to normal surrounding tissue, thereby enhancing
contrast and enabling a differentiation between the tumor and
surrounding tissue. This phenomenon is also known as the
enhanced permeability and retention (EPR) effect.
Many non-targeted fluorescent probes have already been used in
humans to enhance contrast during surgery in a variety of different
indications, such as for example fluorescein for retinal fluorescein
angiography, indocyanine green (ICG) for liver perfusion47–49 and
lymph node detection,50,51 or methylene blue for sentinel lymph node
detection in breast cancer patients.52,53
ICG is the most commonly known fluorescent probe, which was
already approved by the Food and Drug Administration (FDA) back in
1959. ICG has several advantages over to fluorescein as it only
fluoresces in the NIR light spectrum (instead of the visible light
spectrum) and therefore is less influenced by tissue optical properties
such as scattering and absorption. As ICG binds to plasma proteins, it
has a negligible toxicity and is excreted rapidly by the liver into the bile,
with a plasma half-life of only 3-4min.54,55 These features make ICG a
very attractive contrast agent for assessment of macro- and micro-
circulatory status of different organs based on its intravascular
distribution.56
Ever since its first clinical application in hepatology for liver
condition monitoring in 1957,57 it has been widely applied and
studied to visualize perfusion in ophthalmology for identification of
retinal blood vessels, in cardiac bypass surgery for evaluation of
anastomoses and for monitoring cardiac output.58–62 More recent
studies have reported the potential application of ICG for
intraoperative fluorescence angiography in a broad range of other
indications such as neuro-, coronary-, reconstructive-, liver-, and
vascular surgery.59,63–70
The first potential application of ICG-based fluorescence imaging
in patients with peritoneal metastases of colorectal origin was
demonstrated in 2016.71 In this study, peritoneal metastases from
non-mucinous adenocarcinoma were accurately identified following
the intravenous administration of free ICG during surgery, leading to
an adjustment in clinical decision making in 29% of patients. However,
the benefit was minimal in patients with mucinous adenocarcinoma.
Despite the positive results demonstrated in this study, the main
disadvantage still lies in the fact it is not tumor-specific and therefore
leads to a low sensitivity and specificity.
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5.2 | Targeted fluorescent probes
Due to the low sensitivity and specificity of non-targeted
fluorescence probes, its application in surgical oncology is still
limited. Therefore, to increase contrast, this resulted in a shift
toward the development and clinical translation of targeted optical
imaging agents enhancing surgical vision based on the molecular
characteristics of cancer cells.
The MOA of targeted fluorescent probes is based on the
concept of a carrier molecule that is conjugated to a fluorescent
dye, specifically binding to a certain tumor target. Carrier
molecules can either be monoclonal antibodies, (small) peptides,
small molecules, or other molecules that specifically target certain
cell surface markers that become overexpressed due to genetic
variances that occur in every tumor (Figure 3B).72 Moreover, the
increased metabolic activity that characterizes certain tumor types
can be used as a target.40
Besides a suitable carrier molecule, the fluorescent dye itself
also plays an important role. The development of new fluores-
cence probes is challenging since each agent needs separate
regulatory approval, which is an expensive and time-consuming
process.73 As mentioned before, fluorescent dyes that emit light
in the NIR light spectrum provide several advantages over dyes
that emit light in the visible light spectrum. Although there is a
wide variety of fluorescent dyes available for conjugation to
carrier molecules, the most preclinical and clinical experience has
been obtained with the NIR fluorescent dye IRDye800CW,
developed by LI-COR Biosciences Inc. (Lincoln, NE). The
IRDye800CW has a peak emission wavelength at 794 nm and is
ideal for protein and antibody labeling, as conjugation to a carrier
molecule is relatively easy and extensive toxicity studies have
been performed.74
The increasing clinical application of therapeutic monoclonal
antibodies specifically targeting certain biomarkers of cancer is an
interesting development in the perspective of optical molecular
imaging. Targeting certain tumor-specific receptors with fluorescently
labeled antibodies seems to have great potential for visualization of
cancer during interventions, also in CRC.72,75–78 Multiple targeted
probes have already been testes successfully in several preclinical
studies.75,77–84
The first in-human proof-or-principle of targeted optical molecular
imaging using a fluorescent probe was provided by van Dam et al24 in
2011, demonstrating the potential of MFGS in patients with PC
originating from ovarian cancer using the fluorescent tracer
FIGURE 3 Fluorescence imaging probes. Overview of fluorescent imaging probes with different mechanisms of action. The effect of
non-targeted fluorescent probes is based on tissue distribution by perfusion (A), whereas antibody-based (B), peptide-based (C), and small
molecule- based (D) imaging enables targeted fluorescence imaging through binding to specific receptors or proteins overexpressed by
the tumor. Smart activatable fluorescent probes are activated upon cleavage by specific enzymes or proteases secreted by the tumor (E),
whereas pH activated probes becomes fluorescent through a change in molecular structure due to the characteristic acidotic environment
of a tumor (F)
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folate-FITC, targeting the folate receptorα. Ever since, targeted optical
imaging has been applied for many different indications.
6 | POTENTIAL FLUORESCENCE IMAGING
AGENTS FOR DETECTION OF COLORECTAL
CANCER
As mentioned before, using the TASC scoring system, seven potential
targets for optical molecular imaging of PC of colorectal origin have
been identified: CXCR4, EpCAM, EGFR, CEA, Muc1, MMPs, and
VEGF-A.46 The specifics of these proteins and receptors are
summarized in Table 1.85–109 Several fluorescent imaging probes
targeting these biomarkers have already been investigated in humans
in a broad variety of indications.
For example, the NIR fluorescent tracer cetuximab-800CW
targeting EGFR has been applied in humans for surgical navigation
in head-and-neck squamous cell carcinoma.92 Moreover, cetuximab-
800CW is being used in a phase-I clinical trial in the UniversityMedical
Center Groningen in patients with head and neck squamous cell
carcinoma (NCT03134846).
Besides, the NIR fluorescent tracer bevacizumab-800CW target-
ing VEGF-A has been applied for detection of a variety of different
tumor types, among which locally advanced rectal cancer
(NCT01972373), pancreatic cancer (NCT02743975), breast cancer109
(NCT02583568), and esophageal cancer.108 The feasibility of MFGS
using bevacizumab-800CW is also being investigated for intra-
operative guidance in benign diseases such as endometriosis
(NCT02975219) or for endoscopic detection of familial adenomatous
polyposis (NCT02113202).
In CRC and specifically peritoneal metastases of colorectal origin,
so far two phase-I feasibility studies have been performed in humans.
7 | FEASABILITY STUDIES IN PC OF
COLORECTAL ORIGIN
In 2016, Harlaar et al107 used the NIR fluorescent tracer
bevacizumab-RDye800CW targeting VEGF-A for MFGS in seven
patients with PC from CRC origin, that were scheduled to undergo
CRS and HIPEC. Intravenous administration of bevacizumab-800CW
3 days prior to surgery proved to be safe, as no (serious) adverse
events that were related to tracer administration occurred in any of
the patients. Fluorescence signals were observed in all patients
during surgery. Additional tumor tissue that had not been identified
by the surgeons using only visual and tactile inspection was detected
in two patients using fluorescence imaging. The fresh surgical
specimens were imaged back-table at the operating theatre. A total
of 80 peritoneal areas were imaged using the intraoperative camera
system and analyzed by a pathologist. All 29 resected, but non-
fluorescent areas proved to be benign on final histopathology, thus
potentially indicating a sensitivity of 100%. In 27 out of 57
fluorescent areas in the fresh surgical specimen, tumor tissue was
identified. Although the authors state that their study was not
powered to investigate the sensitivity and specificity, the results are
very promising. In conclusion, in this study MFGS using bevacizu-
mab-800CW was safe and feasible and could potentially improve
CRS and patient selection.
The second feasibility study was performed in 2018 by Boogerd
et al,96 in which SGM-101, a fluorescent anti-CEA monoclonal
antibody, was administered intravenously 2–4 days before surgery,
to investigate the feasibility of MFGS in CRC and PC of colorectal
origin. Patients with PC of colorectal origin that were scheduled for
open surgical removal were included. First, a dose-finding study was
performed in the first nine patients. Subsequently, the most optimal
dose of SGM-101 was investigated in another 17 patients. SGM-101
showed no treatment-related (serious) adverse events. However, a
total of eight possibly relatedmild adverse events occurred throughout
the study. Using MFGS, in six patients a total of 19 additional
peritoneal lesions were identified as potentially tumor-positive, and
therefore treatment strategies were changed. The authors report a
sensitivity of 98% and a specificity of 62%.
Interestingly, although both studies used different fluorescent
tracers, more or less the same conclusions were drawn. Most
importantly, both bevacizumab-800CW and SGM-101 were deemed
safe in combination with MFGS. Moreover, it appeared that with both
fluorescent tracers, a very high sensitivity could be obtained. If these
results are validated in a larger patient cohort and indeed clinically
suspect, but non-fluorescent lesions turn out to be benign, non-
fluorescent lesions may be left in situ in the future and subsequently
decrease morbidity. Interestingly, this might also imply that currently
visual and tactile inspection-based surgery leads to unnecessary
resections when compared to MFGS. The majority of complications
and revalidation time is probably related to the extent of the
cytoreduction itself. This might also improve the current morbidity
of 22-34% and mortality of 0.8-4.1%.110–115
The specificity in these two feasibility studies appears to be
relatively low, with a substantial amount of false positive lesions when
applying intraoperative fluorescence imaging. This might be due to
technical limitations of the fluorescence camera system that still need
to be improved, such as the multispectral substration techniques.
Currently, quantification of fluorescence with most of the present
generation of clinically approved fluorescence camera systems is still
limited, making the interpretation of fluorescence signals subjective. If
a threshold could be set to give the surgeon a “yes” or “no” answer to
the question whether a peritoneal lesion is tumor-positive with a
certain sensitivity and specificity, this could potentially improve
interpretation of fluorescence signals. Last, for some tracers, the
optimal dose might still need further optimization.107
Additional research and studies need to be performed to
investigate novel fluorescence imaging agents in humans for MFGS
of PC of colorectal origin. Theoretically, multiple fluorescence imaging
agents can be intravenously administered to the same patients
simultaneously, a so-called “tracer cocktail,” in order to improve
sensitivity and specificity. Therefore, novel fluorescence imaging
agents need to be validated in a standardized way, with the emphasis
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on the determination of the safety, feasibility, optimal agent dose, and
optimal timing for surgical intervention in phase-I feasibility studies.
8 | FUTURE PERSPECTIVES
8.1 | Target selection for MFGS
Currently, there are many carrier molecules that seem promising for
potential validation in phase-I feasibility studies according to the TASC
scoring system.46 Additionally, new strategies have been developed
recently to identity biomarkers that are upregulated in cancer
development, such as functional genomic mRNA (FGM) profiling.116
This method corrects expression data of numerous genes for relevant
non-genetic variables. It is likely that in the near future new promising
targets will be identified by this gene expression analysis, that may be
used as targets, providing new possibilities for imaging of PC of
colorectal origin.
8.2 | Novel fluorescence imaging probes
Next to the validation of potential targets for imaging, novel
fluorescent probes are being developed.72,117 Different types of
carrier molecules have different pharmacokinetics. The substantial
molecular weight of monoclonal antibodies (generally ± 150 kDa,
Figure 3B) results in a relatively long blood circulation time of
several days up to weeks. Although there is extensive experience
with the use of monoclonal antibodies, even smaller molecules may
provide favorable pharmacokinetic properties, such as nano-
bodies.118 A faster clearance from background tissue results in
sufficient signal-to-background ratios that occur within a much
shorter period of time. Therefore, peptides or small molecules
might be logistically favorable compared to antibodies for MFGS
(Figures 3C and D).118 On the other hand, smaller molecules are in
general more difficult to conjugate to a fluorescence dye, as even
small structural changes can influence pharmacokinetics and
binding efficacy significantly.118,119
Another subgroup of imaging probes has come forward in recent
years: targeted smart-activatable probes (Figure 3E).119 The working
mechanism of these probes is based on the principle of photochemical
quenching or ligand-targeted activation. Smart activatable probes only
fluoresce when bound to the tumor or cleaved by specific proteases or
peptidases excreted by the tumor, which improves signal-to-back-
ground ratios due to limited background fluorescence.118,120 The first
clinical studies to investigate smart activatable probes have been
performed already.117 However, to the best of our knowledge, this has
not yet been done for intraoperative imaging of CRC or PC of
colorectal origin.
A similar “on-or-off” concept has been applied in the development
of a pH-activatable fluorescent probe. This probe becomes activated
upon contact with a certain threshold pH (pH ≤ 6.9), as the majority of
solid tumors are acidotic. Although this probe does not target a tumor
biomarker, it is still highly specific due to the pH transistor concept.121
The benefit of such a probe is that it can be applied in a broad range of
oncological indications. However, the first proof-of-concept in human
study using a pH-activated probe still needs to be conducted.
8.3 | Phase II/III clinical studies
Although different fluorescent probes are being developed, so far only
two phase-I feasibility studies have been finalized in relatively small
numbers of patients with PC of colorectal origin.96,107 The ability of
fluorescence imaging to detect peritoneal metastases that are missed
by visual and tactile inspection and to aid in the differentiation
between malignant and benign tissue, may have the potential to
change clinical decision making. Although these results seem
promising, further validation in phase-II clinical studies is required,
with larger patient cohorts that are sufficiently powered to estimate
the diagnostic accuracy. Eventually, in phase-III studies, the impact of
MFGS in CRS and HIPEC surgery on clinical endpoints such as
progression-free and overall survival need to be evaluated, hoping to
improve the current median progression-free survival of only 12.6
months.11
8.4 | Photodynamic therapy
Although current clinical studies are mainly aimed to investigate the
feasibility of optical imaging for cancer detection, in the future
intraoperative imaging may also be used as a therapeutic modality.
Carrier molecules that specifically target the tumor can also be labeled
to a photoactive dye (ie, photosensitizer), to allow targeted
photodynamic therapy (tPDT). When excited with light of a specific
wavelength, photosensitizers not only fluoresce, but also form reactive
oxygen species that oxidize the cells they target, thereby killing
them.122 Potentially, tPDT may be applied after CRS, to assist in the
elimination of microscopic peritoneal lesions. As there is only
superficial activation of the targeted photosensitizers, side-effects
are estimated to be limited. The first clinical trials have already been
performed to investigate the safety and feasibility of tPDT using a
variety of different photosensitizers. Phase I and II clinical trials have
been conducted for treatment of colorectal cancer,123 pelvic recur-
rence of CRC,124 colorectal liver metastases (NCT00068068),125 and
locally advanced rectal cancer.126 Moreover, tPDT has also been
applied for the treatment of peritoneal metastases originating from
ovarian cancer and sarcomas,127 and different gastrointestinal
tumors128 with promising results. These studies demonstrate that
tPDT could potentially be used as an effective treatment for both CRC
and PC. However, future studies are required to determine the effect
on PC of colorectal origin, when combined with MFGS.
9 | CONCLUSION
In conclusion, treatment of PC of colorectal origin with curative intent
consists of CRS followed by HIPEC. Up to date, surgeons still rely on
visual and tactile inspection for intraoperative differentiation between
tumor and benign tissue. The ultimate goal during cytoreduction is to
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obtain a macroscopically complete cytoreduction by resecting
malignant tissue only. Therefore, there is a clear need for an
intraoperative imaging technique improving tumor detection. The
first phase-I clinical trials have been performed showing the potential
benefit of MFGS for patients with PC of colorectal origin. Even though
no conclusions can be drawnwith regard to the impact of these studies
on clinical decision making, it appears MFGS has the potential to
improve both cytoreduction and patient selection, facilitating patient-
tailored surgery. However, to reliably determine the sensitivity and
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